NOTTINGHAM, England, July 10,
2024 /PRNewswire/ -- IsomAb Ltd, a
UK-based biotechnology company developing
isoform-specific disease modifying antibody treatments for
serious and life-threatening diseases, today announced the
expansion of its Clinical Advisory Board (CAB); the key role will
be to provide expert clinical knowledge and advice on future
clinical trials for the company's lead programme. The CAB consists
of renowned international experts in the fields of vascular surgery
and management of diabetic patients with vascular complications.
Many of the CAB members have collaborated on recent clinical trials
in limb ischaemia including the PACE PIII trial1
Jackie Turnbull, CEO of IsomAb
Ltd, said: "The expansion of our Clinical Advisory Board
comes at an exciting time for our Company as we continue to
generate preclinical data in support of ISM-001, a high
affinity, humanised antibody designed to restore blood flow in
diabetic vascular disease. As we advance our program, we
have access to an extraordinary group of renowned clinical experts,
who will provide key insights and recommendations to help guide the
clinical trial program."
The Clinical Advisory Board consists of the following
members:
Prof. Dr. Maarit Venermo – CAB Chair
Professor Venermo is head of the department of vascular surgery
at Helsinki University Hospital. Her
research concerns registry studies aiming to evaluate the quality
of vascular surgical service as well as international variation in
practice. Professor Venermo is currently the Secretary General of
the European Society for Vascular Surgery (ESVS) and has been a
member, or other role, of eleven national/international committees,
councils and boards. She has been named on 276 publications in the
field of vascular surgery.
Prof. Dr. med. Sigrid
Nikol
Professor Nikol trained in thoracic and cardiovascular surgery
early in her career, then became an
interventional cardiologist and interventional vascular
physician. She is Head of Department of Interventional Angiology,
St. Georg Hospital in Hamburg
Germany. She worked in the early nineties with the
pioneer of angiogenesis therapy, Jeffrey
Isner MD in Boston,
USA. She has over 30 years of
experience in translational angiogenesis research, which includes
preclinical work and active roles in numerous clinical angiogenesis
trials, as Principal Investigator as well as being a member of
numerous Steering Committees or Advisory Boards. She has
authored more than 231 publications in the cardiovascular field
including current guidelines. She is past-president of the
European Society for Vascular Medicine (ESVM), a member of the
German Angiology Society, and the International Andreas Gruentzig
Society.
Professor Robert
Hinchliffe
Professor Hinchliffe is a Clinical Professor of Vascular Surgery
at Bristol Medical School, and the Chair for the Research for
Patient Benefit Southwest region. He is Honorary Consultant
Vascular Surgeon in the Bristol,
Bath, Weston Vascular Network and an academic vascular surgeon with
an interest in diabetes related complications of the lower limb and
peripheral artery disease. His research interest is in clinical
trials and the evaluation of innovative technologies in
surgery.
Marc P. Bonaca, M.D.,
MPH
Marc P. Bonaca, MD, MPH is a
Cardiologist and Vascular Medicine Specialist who serves as the
Executive Director of CPC Clinical Research and CPC Community
Health at the University of Colorado.
He is the Director of Vascular Research and an Associate Professor
of Medicine at the University of
Colorado School of Medicine and the inaugural holder of the
William R. Hiatt Endowed Chair in Cardiovascular Research. He is a
member of the Society of Vascular Medicine, American College of
Cardiology (ACC) and American Heart Association (AHA). He currently
serves on the ACC PVD Leadership Council and is an associate editor
for the Vascular Medicine.
Professor John C.
Lantis
Professor Lantis II, MD, is currently the site Chief and
Professor of Surgery at Mount Sinai West Hospital, and the Icahn
School of Medicine; in mid-town Manhattan where he practices as a senior
vascular surgeon. He is the past president of the New York Vascular
Surgery Society, a founding member of the American Board of Wound
Medicine and Surgery, and the Vascular Study Group of New
York. He is a world leader in limb salvage and lower
extremity wound healing and has been a principal investigator on
over 70 clinical trials.
Joseph L. Mills, M.D.,
FACS
Joseph L. Mills, M.D. is a
board-certified vascular surgeon in Houston, Texas specializing in diabetic foot
amputation prevention and limb salvage. Dr. Mills has authored
nearly 300 peer-reviewed journal articles and book chapters,
focused on his clinical and research interests in non-invasive
diagnosis, vein graft stenosis, intimal hyperplasia and
limb-salvage in patients with diabetes mellitus. He has been the
principal investigator for over 40 clinical trials, including a
number of current investigations.
Professor Michael
Edmonds
Professor Edmonds is a Consultant Physician at King's College
Hospital in London with a special
responsibility for care of the diabetic foot. He developed a
multi-disciplinary diabetic foot clinic in 1981, one of the first
in the world. He won the Karel Bakker award at the
6th International Symposium on the Diabetic Foot in
2011 and more recently in 2013 the DFSG Achievement Award. He
has also won the Edward James Olmos award for the advocacy in
amputation prevention at the DF Con 2014 and gave the Arnold Bloom
lecture at Diabetes UK in 2015.
Professor Stephen Bain
Professor Bain is the Clinical Director of the Diabetes Research
Unit at Swansea University and
Medical Director for Research & Development for Swansea Bay
University Health Board. He is also the Chair of the National
Specialist Advisory Group (NSAG) for Diabetes in Wales and has been Chief Investigator for
several multi-centre trials investigating novel therapies for
diabetes; these include LEADER, SUSTAIN 6, PIONEER 6 and most
recently SOUL.
1 - PACE: randomized, controlled,
multicentre, multinational, phase III study of PLX-PAD for critical
limb ischaemia in patients unsuitable for revascularization:
randomized clinical trial. January
2024; BJS (British Journal of Surgery) 111(2)
For further information please contact: IsomAb Ltd; E:
info@isomab.bio
Notes to Editors
About IsomAb Ltd
IsomAb Ltd, founded in 2022, is a UK-based biopharmaceutical
company and is a spin-out from the University of Nottingham; early research was conducted at
the University of Bristol and
funding has been received from the British Heard Foundation,
Wellcome Trust and the Medical Research Council. The Company was
founded by Prof. David Bates and
Prof. Steve Harper based on
ground-breaking research into VEGF-A and its splice isoforms and
focusses on the development of isoform specific antibodies for
disease modifying treatment of life limiting diseases with
peripheral ischaemia. ISM-001 is high affinity, humanised antibody
to restore blood flow in diabetic vascular disease. For more
information, visit: www.isomab.bio.
Logo -
https://mma.prnewswire.com/media/2457243/Isomab_logo.jpg
View original content to download
multimedia:https://www.prnewswire.com/news-releases/isomab-announces-the-expansion-of-its-clinical-advisory-board-302192278.html
SOURCE IsomAb